In a prospective, open-label phase 1b/2a proof-of-concept study (MG-001), the safety and efficacy of this approach was investigated in 14 patients with generalized MG, of whom 2 patients were MuSK-Ab positive (167). The gene discussed is MUSK; the disease is myasthenia gravis.